BCR-ABL1 Kinase Domain Mutation Analysis in UAE | 1500 AED | DHA Licensed

Executive Summary & Core Metrics

✔ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited processing.
✔ Logistics: Hospital‑only sample collection – bone marrow aspirate performed in accredited hospital; no mobile home phlebotomy available.
✔ Clinical Guidance: Telephonic post‑test clinical guidance for result interpretation — connect with our clinical team.
✔ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

BCR‑ABL1 Kinase Domain Mutation Analysis detects specific point mutations within the kinase domain of the BCR‑ABL1 fusion gene, pinpointing resistance to first‑line tyrosine kinase inhibitors such as imatinib. This Sanger sequencing‑based test guides clinicians in selecting the appropriate next‑generation TKI for chronic myeloid leukemia patients.

Feature	Our Test (BCR‑ABL1 Kinase Domain Mutation Analysis)	Closest Alternative (BCR‑ABL1 Quantitative RT‑PCR)
Precision / Method	Gold‑standard Sanger Sequencing for mutation identification	Real‑Time PCR measures transcript levels, not mutations
Clinical Utility	Detects resistance‑conferring mutations (e.g., T315I) to guide TKI switch	Monitors minimal residual disease but cannot explain resistance mechanism
Speed / TAT	7–8 days	3–5 days

Physician Insight & Safety Protocols

“This analysis is a cornerstone in personalizing treatment for CML patients. As a genetics specialist, I emphasize that mutation detection guides the choice of next‑generation tyrosine kinase inhibitors. However, results must always be correlated with clinical and haematological parameters. Any modification to therapy must be discussed with the treating physician.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Medication Advisory

⚠️ Do not discontinue prescribed tyrosine kinase inhibitor therapy without consulting your doctor. Sudden cessation may lead to disease progression.

Patient Safety Exclusion Criteria & Emergency Red Flags

Exclusion: Uncontrolled bleeding disorders, active infection at the collection site, recent anticoagulant therapy without physician clearance, or inability to provide informed consent.
Exclusion: Bone marrow collection requires evaluation of coagulation profile and platelet count; discuss with your physician if you are on blood thinners.
ER Red Flags: If you experience severe dizziness, chest pain, difficulty breathing, or prolonged bleeding after sample collection, seek emergency medical attention immediately.
Safety Note: All hospital collections are performed by DHA‑licensed professionals under strict aseptic protocols; do not delay reporting any unusual symptoms.

Patient FAQ & Clinical Guidance

1. What is BCR‑ABL1 kinase domain mutation analysis?

Direct Answer: It is a molecular genetic test that detects mutations in the BCR‑ABL1 gene causing resistance to tyrosine kinase inhibitors like imatinib. Results help your doctor select the most effective next‑line therapy.

2. Why is this test needed?

Direct Answer: This test is essential for CML patients who show suboptimal response or resistance to imatinib. It identifies actionable mutations such as T315I, enabling a targeted switch to second‑ or third‑generation TKIs.

3. How is the sample collected?

Direct Answer: Hospital extraction only – sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. The physician will determine whether a peripheral blood draw or bone marrow aspirate is appropriate.

4. Do I need a prescription?

Direct Answer: Yes, a valid doctor’s prescription is required for this test, except for patients undergoing surgery, pregnancy monitoring, or pre‑travel medical clearance as per DHA guidelines.

5. How long do results take?

Direct Answer: The turnaround time is 7–8 business days from sample collection. You will receive a detailed report along with a telephonic clinical guidance session.

UAE Regulatory & Data Privacy Adherence

Compliant with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Clinical safety and patient consent adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability.
For minors, mandatory parental consent is obtained in accordance with UAE child protection regulations.
ISO 9001:2015 Certified Facility (Cert: INT/EGQ/2509DA/3139) — ensuring quality management and patient safety.
Direct Billing & Insurance Support via WhatsApp: +971 54 548 8731.

Clinical & Logistical Metadata

Test Name	BCR‑ABL1 Kinase Domain Mutation Analysis
Price (AED)	1,500
Turnaround Time	7–8 business days
Sample Type / Matrix	Peripheral blood (whole blood) or Bone marrow aspirate – hospital collection only
Methodology Used	Sanger Sequencing
ICD‑10‑CM Code	C92.1 (Chronic myeloid leukemia, BCR/ABL‑positive)
LOINC Code	92836‑6 (BCR/ABL1 kinase domain mutation analysis in Blood)
DHA Facility License & Lab Address	License No. 1143 – DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE